Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-HER2 CAR-CD28 T cells

A preparation of autologous T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) human epidermal growth factor 2 (HER2; ErbB2; HER-2) and coupled to the costimulatory domain of CD28, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-HER2 CAR-CD28 T cells target and bind to HER2-expressing tumor cells, thereby inducing selective toxicity in HER2-expressing tumor cells. HER2 is overexpressed in a variety of cancer cell types and is associated with increased tumor cell proliferation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:Autologous Anti-HER2 CAR-CD28 T-cells
autologous anti-HER2 CAR-CD28-expressing T cells
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search